BrainStorm reports Q3 EPS (25c), consensus (22c)

"On October 11, 2019 we reached a major corporate milestone by fully enrolling 200 patients in the Phase 3 clinical trial of NurOwn in ALS. Additionally, on October 28, we announced that we received notification from the NurOwn Data Safety Monitoring Board that after reviewing all of the safety data as of September 30, the study should continue without any changes in the protocol. The DSMB indicated they did not identify any significant safety concerns," stated Chaim Lebovits, President and CEO of BrainStorm Cell Therapeutics. He added, "Our Phase 2 trial of NurOwn in Progressive MS continues to enroll patients in several of the leading U.S. medical centers and we anticipate announcing additional investigational centers of excellence in the near future. The first eight participants have been enrolled in the study." Cash, cash equivalents, and short-term bank deposits were $2.1M at September 30, compared to $2.7M at June 30.